ES3045907T3 - Composition for preventing or treating neurotrophic keratitis which contains stabilized pacap peptide - Google Patents

Composition for preventing or treating neurotrophic keratitis which contains stabilized pacap peptide

Info

Publication number
ES3045907T3
ES3045907T3 ES20806275T ES20806275T ES3045907T3 ES 3045907 T3 ES3045907 T3 ES 3045907T3 ES 20806275 T ES20806275 T ES 20806275T ES 20806275 T ES20806275 T ES 20806275T ES 3045907 T3 ES3045907 T3 ES 3045907T3
Authority
ES
Spain
Prior art keywords
peptide
seq
sequence
amino acid
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20806275T
Other languages
English (en)
Spanish (es)
Inventor
Takeshi Nakajima
Mamiko Machida
Shuhei Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES3045907T3 publication Critical patent/ES3045907T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
ES20806275T 2019-05-14 2020-05-14 Composition for preventing or treating neurotrophic keratitis which contains stabilized pacap peptide Active ES3045907T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019091700 2019-05-14
PCT/JP2020/019347 WO2020230869A1 (ja) 2019-05-14 2020-05-14 Ｐａｃａｐペプチド又はｐａｃａｐの安定化ペプチドを含む神経栄養性角膜炎の予防又は治療用組成物

Publications (1)

Publication Number Publication Date
ES3045907T3 true ES3045907T3 (en) 2025-12-01

Family

ID=73289423

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20806275T Active ES3045907T3 (en) 2019-05-14 2020-05-14 Composition for preventing or treating neurotrophic keratitis which contains stabilized pacap peptide

Country Status (6)

Country Link
US (1) US20220202905A1 (https=)
EP (1) EP3970796B1 (https=)
JP (2) JPWO2020230869A1 (https=)
CN (1) CN114173874B (https=)
ES (1) ES3045907T3 (https=)
WO (1) WO2020230869A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202400628A (zh) * 2022-06-24 2024-01-01 全福生物科技股份有限公司 用於治療神經營養性角膜炎疾病之包含pedf衍生短肽之組合物
WO2024102746A1 (en) * 2022-11-08 2024-05-16 Microcures, Inc. Methods and agents for treating neurotrophic keratitis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198542A (en) * 1989-06-20 1993-03-30 Takeda Chemical Industries, Inc. Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
JPH10505863A (ja) * 1994-09-22 1998-06-09 ジ・アドミニストレーターズ・オブ・ザ・チューレン・エデュケイショナル・ファンド 脳障害の予防および治療のための方法および医薬組成物
US20020155533A1 (en) * 1998-11-30 2002-10-24 Takeda Chemical PACAP receptor protein, method for preparing said protein, and use thereof
JP2001151799A (ja) * 1999-11-22 2001-06-05 Itoham Foods Inc 新規ペプチド及びそれを含有する消化管運動抑制剤
WO2003051387A1 (fr) * 2001-12-19 2003-06-26 Itoham Foods Inc. Agents therapeutiques et/ou prophylactiques contre des maladies conformationnelles
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
KR20070036031A (ko) * 2004-04-23 2007-04-02 센주 세이야꾸 가부시키가이샤 Ｐａｃａｐ 및 이의 유도체를 함유하는 각막 신경세포 형성촉진제
JP2009269818A (ja) 2006-08-22 2009-11-19 Univ Showa Ｐａｃａｐペプチドを含む眼科用剤
WO2010036936A2 (en) * 2008-09-25 2010-04-01 The Administrators Of The Tulane Educational Fund Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents
US8916517B2 (en) * 2009-11-02 2014-12-23 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
CN101745098A (zh) * 2010-01-26 2010-06-23 暨南大学 神经多肽pacap38在制备眼部疾病的治疗、损伤修复或再生药物中的应用
WO2012127475A1 (en) 2011-03-24 2012-09-27 Neurim Pharmaceuticals (1991) Ltd. Neuroprotective peptides
JP5775356B2 (ja) 2011-05-09 2015-09-09 松本　明 神経保護作用を有するペプチド及びこれを含む薬剤
CU24075B1 (es) * 2011-08-26 2015-01-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.
CN103145851B (zh) * 2013-02-22 2014-07-02 暨南大学 重组蛋白PACAP38-NtA及其编码基因与应用
WO2017027848A1 (en) 2015-08-12 2017-02-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier
AT520342A1 (de) * 2017-09-07 2019-03-15 Ventrex Automotive Gmbh Ventil zum Einsatz im Tieftemperaturbereich sowie Verwendung dieses Ventils

Also Published As

Publication number Publication date
WO2020230869A1 (ja) 2020-11-19
EP3970796A4 (en) 2022-12-21
CN114173874A (zh) 2022-03-11
EP3970796A1 (en) 2022-03-23
CN114173874B (zh) 2025-07-25
US20220202905A1 (en) 2022-06-30
JP2025108784A (ja) 2025-07-23
JPWO2020230869A1 (https=) 2020-11-19
EP3970796B1 (en) 2025-08-20

Similar Documents

Publication Publication Date Title
CA3023670C (en) Differentiation Cluster Agonists 47 Inducing Programmed Cell Death (PCD) and Their Use in the Treatment of Diseases Associated with Defects in Programmed Cell Death
ES2766755T3 (es) Análogos de compstatina con propiedades farmacocinéticas mejoradas
ES2481915T3 (es) Utilización de inhibidores peptídicos permeables celulares de la vía de transducción de señales jnk para el tratamiento de diversas enfermedades
ES2784551T3 (es) Nuevas moléculas inhibidoras de JNK para el tratamiento de varias enfermedades
ES2622385T3 (es) Miméticos de factor de crecimiento de hepatocitos como agentes terapéuticos
ES2650543T3 (es) Trastornos neurodegenerativos
ES2439950T3 (es) Péptidos con permeabilidad celular inhibidores de la ruta de transducción de señales de la JNK
JP2025108784A (ja) Ｐａｃａｐペプチド又はｐａｃａｐの安定化ペプチドを含む神経栄養性角膜炎の予防又は治療用組成物
US20140094413A1 (en) Hepatocyte growth factor (hgf) mimics as therapeutic agents
ES2433568T3 (es) Análogos sintéticos de péptidos de regeneración neuronal
US9561256B2 (en) LLP2A-bisphosphonate conjugates for osteoporosis treatment
ES2559634T3 (es) Péptidos derivados de NCAM (FGLs)
US20020142966A1 (en) Inhibitors of the E2F-1/cyclin interaction for cancer therapy
US11566047B2 (en) Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof
JPWO2017170924A1 (ja) 神経保護ペプチド
CN109414475A (zh) 新型肽和肽模拟物
US12304932B2 (en) PACAP stabilized peptide
ES2991433T3 (es) Péptido de PACAP estabilizado
CN114746121A (zh) 五肽及其使用方法
WO2010092577A2 (en) COMPLEMENT C3a DERIVED DIMERIC PEPTIDES AND USES THEREOF
JP2020059663A (ja) ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ
KR20250077606A (ko) 변형된 카베올린-1 펩타이드 제형 그리고 이의 제조 방법 및 용도
CA3213849A1 (en) C-met protein-binding peptide complex
JP2023526515A (ja) リソソーム蓄積症をヒスタチンペプチドで処置するための方法
JPWO2017170926A1 (ja) 神経保護ペプチド